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G
enotoxicology investigates the molecular basis of 
cellular responses to DNA damage. During more 
than three decades of genetic toxicology testing, a 
large number of tests with varying sensitivity and specificity 
have been developed. 
These genotoxicity tests can predict:
•  the likelihood of a substance to be a (rodent) carcinogen,
•  the  mechanism  of  carcinogenic  activity  of  different 
substances,
•  if the results of genotoxicity studies only predict carcino-
genicity or they are a distinct hazard endpoint (Nohynek, 
2005). 
The current genetic toxicity testing batteries represent:
•  Ames test which is a component of all genetic testing 
batteries.
•  A mammalian cell mutagenicity assay which should 
confirm or complete the Ames test.
•  Chromosomal aberrations tests which are based on a 
different endpoint than gene mutations.
•  Positive in vitro results need to be confirmed by in vivo 
tests; results from test batteries have higher predictive 
value than results of a single test (Nohynek, 2005). 
The human molecular epidemiology represents a new 
trend in the study of genetic susceptibility and interactions 
between genetic and environmental factors of risk. Doses 
and biochemical effects biomonitoring have nowadays a 
tremendous utility providing an efficient means of mea-
suring human exposure to chemical substances. Human 
biomonitoring considers all routes of uptake and all sources 
which are relevant making it an ideal instrument for risk 
assessment and risk management; blood is by far the most 
approved matrice. Human biomonitoring can be done for 
most chemical substances which are in the focus of the 
worldwide discussion of environmental medicine (Angerer 
et al., 2007). Molecular epidemiology studies of human 
populations exposed to potential mutagens have the aim 
to assess the risk of genetic disease or cancer by analysing 
the relationship between internal exposure and biological 
effects in target cells under consideration of confounding 
factors  (Faust  et  al.,  2004).  Human  biomonitoring  can 
identify new chemical exposures, trends and changes in 
exposure, establish distribution of exposure among the gen-
eral population, identify vulnerable groups and populations 
with higher exposures and identify environmental risks 
at specific contaminated sites. The sensitivity of methods 
moreover enables the elucidation of human metabolism and 
toxic mechanisms of the pollutants (Angerer et al., 2007).
Biomarkers of effect that indicate exposure to a causative 
agent and that reflect the individual risk of disease are 
numerous. The most commonly used biomarkers in cancer 
epidemiology include: measurements of DNA damage, such 
as DNA breaks, altered bases, bulky adducts; chromosomal 
aberrations (CA), micronuclei (MN) and sister chromatid 
exchange (SCE), which are also the results of DNA damage 
(Kassie et al., 2000; Collins, 1998). Chromosomal aberra-
tions and micronuclei are biomarkers of damage due to 
genetic instability or exposure to environmental mutagens 
or carcinogens. A recent approach is to associate the bio-
markers of genetic susceptibility which take into account 
cancer susceptibility and interindividual differences in the 
response to a genotoxic exposure, and the analysis of CA 
and/or MN, which serves as a biomarker of interactions 
between the environment and the genetic material of the 
cell. Information is being gathered on how DNA damage 
and more particularly the frequency of chromosomal aber-
rations and/or micronuclei depend on the polymorphisms in 
genes implicated in xenobiotic metabolism (activation and/
or detoxification) and DNA lesion repair. For biomonitoring 
purposes, numerous confounding factors (age, sex, tobacco 
consumption, etc.) influence the CA and MN biomarker, 
and thus associating genetic polymorphisms to CA and MN 
would be useful to better define the prevention and prediction 
of risk (Iarmarcovai et al., 2007a; Iarmarcovai et al., 2007b).
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The in vitro genetic toxicology tests used for regula-
tory purposes measure formation of gene mutations and 
chromosomal changes following DNA damage induced by 
the compounds under test, and are used to predict the carci-
nogenic potential of pharmaceuticals, industrial chemicals, 
food additives and cosmetic ingredients (Kirkland et al., 
2007). In vitro test systems will aid in the identification of 
the most sensitive species and strains. Also, in vitro systems 
are good models for studying qualitative and quantitative 
species differences in toxicity. Further, in vitro systems are 
excellent models for characterisation of the mode of action/
mechanism for critical effects, but findings need to be vali-
dated in vivo. In vitro systems will aid in the extrapolation 
from high to low dose and from experimental animals to 
humans (Holme et al., 2002). 
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